Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.08
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
112
Open
48.08
Bid (Size)
47.99 (13)
Ask (Size)
48.02 (16)
Prev. Close
48.08
Today's Range
48.08 - 48.08
52wk Range
45.22 - 58.97
Shares Outstanding
1,250,690,553
Dividend Yield
4.24%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
December 05, 2024
Via
The Motley Fool
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
December 04, 2024
Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges.
Via
Benzinga
Performance
YTD
-3.84%
-3.84%
1 Month
-5.02%
-5.02%
3 Month
-17.29%
-17.29%
6 Month
-0.89%
-0.89%
1 Year
+1.97%
+1.97%
More News
Read More
NVIDIA Invested in These 2 AI Stocks, Should You?
December 02, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
November 29, 2024
Via
Chartmill
Bird Flu Found In Raw Milk Leads To Recall In California
November 26, 2024
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
Balancing Dividends and Fundamentals: The Case of NASDAQ:SNY.
November 25, 2024
Via
Chartmill
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
November 20, 2024
Via
Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
November 20, 2024
Via
Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
November 15, 2024
Via
Benzinga
Exposures
Product Safety
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
November 15, 2024
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
November 15, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
November 14, 2024
Via
Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
Via
Benzinga
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
November 13, 2024
Via
Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
Via
Benzinga
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.
November 07, 2024
Via
Chartmill
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
November 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
Via
Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
November 01, 2024
Via
Benzinga
Exposures
Product Safety
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
October 31, 2024
Via
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
Via
The Motley Fool
Why Sanofi Stock Flew Higher on Friday
October 25, 2024
Via
The Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
October 25, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
October 25, 2024
Via
Benzinga
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
October 25, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.